Structure Therapeutics' oral obesity drug ​aleniglipron delivered up to 16.3% ‌weight loss when compared with a placebo after 44 weeks of ​treatment in a mid‑stage ​study, it said on Monday.
We break down and simplify the new F1 2026 terminology and regulation changes that focus on sustainability and electrically powered engines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results